Mersana Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Mersana Therapeutics

28/02/2024 16:37

* Mersana Therapeutics Inc  MRSN.OQ  reported a quarterly
adjusted
loss of 16 cents​​ per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of -44 cents.  The mean expectation of
nine analysts for the quarter was for a loss of 16 cents per
share. Wall Street expected results to range from -28 cents
to 22 cents per share.
    * Revenue fell 27.1% to $10.70 million from a year ago;
analysts
expected $14.77 million. 
    * Mersana Therapeutics Inc's reported EPS for the quarter
was a
loss of 16 cents​.
    * The company reported a quarterly loss of $19.54 million.
    * Mersana Therapeutics Inc shares had risen by 84.1% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 23.8%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 5
"hold" and 1 "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Mersana
Therapeutics Inc is $3.00 

This summary was machine generated from LSEG data February 28 at
04:36 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.16          -0.16          Met
 Sep. 30 2023      -0.36          -0.27          Beat
 Jun. 30 2023      -0.44          -0.47          Missed
 Mar. 31 2023      -0.44          -0.52          Missed